LEAP THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Leap Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q3 2024.
  • Leap Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$18.2M, a 32.7% decline year-over-year.
  • Leap Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$64.6M, a 20.3% increase year-over-year.
  • Leap Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$81.4M, a 49.1% decline from 2022.
  • Leap Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$54.6M, a 34.5% decline from 2021.
  • Leap Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$40.6M, a 47.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$64.6M -$18.2M -$4.48M -32.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$60.1M -$20.1M -$6.74M -50.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$53.4M -$13.8M +$28M +67% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$81.4M -$12.5M -$363K -3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$81.1M -$13.7M +$1.4M +9.26% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$82.4M -$13.4M +$3.63M +21.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$86.1M -$41.9M -$31.5M -303% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$54.6M -$12.1M -$1.31M -12.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$53.3M -$15.1M -$3.96M -35.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$49.3M -$17M -$7.5M -78.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$41.8M -$10.4M -$1.24M -13.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$40.6M -$10.8M -$4.08M -60.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 -$36.5M -$11.1M -$4.08M -57.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$32.4M -$9.53M -$3.01M -46.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$29.4M -$9.13M -$1.9M -26.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$27.5M -$6.71M +$1.29M +16.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$28.8M -$7.06M +$878K +11.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$29.7M -$6.52M +$1.85M +22.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$31.5M -$7.23M +$1.37M +15.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$32.9M -$8M -$9.48M -640% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$23.4M -$7.94M -$1.3M -19.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$22.1M -$8.37M -$1M -13.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$21.1M -$8.6M +$2.02M +19% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$23.1M $1.48M +$8.07M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$31.2M -$6.63M +$183K +2.69% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$31.4M -$7.36M -$459K -6.65% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$30.9M -$10.6M -$1.21M -12.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$29.7M -$6.59M -$862K -15% Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 -$28.9M -$6.82M +$462K +6.35% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$29.3M -$6.91M +$572K +7.65% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$29.9M -$9.41M -$4.27M -82.9% Jan 1, 2017 Mar 31, 2017 10-Q/A 2018-08-08
Q4 2016 -$25.6M -$5.73M Oct 1, 2016 Dec 31, 2016 10-K 2018-02-23
Q3 2016 -$7.28M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$7.48M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 -$5.15M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.